Vimarsana
Biggest News Aggregation in the World

Page 2 - Primary Malignancies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary Malignancies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Malignancies Today - Breaking & Trending Today

Johnson & Johnson : Real-World Study Shows Patients Treated with IMBRUVICA® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia - Vimarsana News

Johnson & Johnson : Real-World Study Shows Patients Treated with IMBRUVICA® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia

Published: December 12, 2022

NEW ORLEANS, December 12, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic... | December 12, 2022

Source: marketscreener.com
Related Topics:
United StatesBryan JacobsImran KhanChristie CorbettNone Of The Janssen Pharmaceutical CompaniesAtrium Health Levine Cancer InstituteJanssen Biotech IncAmerican Society Of Hematology Annual MeetingDrug AdministrationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonExchange CommissionAmerican Society Of HematologyDivision Of Lymphoma Therapy ResearchCompanies Of JohnsonDepartment Of Hematologic OncologyAnnual MeetingClinical DirectorLymphoma TherapyHematologic OncologyVice PresidentMedical AffairsJanssen BiotechCardiac Failure
Real-World Study Shows Patients Treated with IMBRUVICA® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia - Vimarsana News

Real-World Study Shows Patients Treated with IMBRUVICA® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia

Published: December 12, 2022

/PRNewswire/ --The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic...

Source: prnewswire.com
Related Topics:
United StatesBryan JacobsImran KhanChristie CorbettNone Of The Janssen Pharmaceutical CompaniesAtrium Health Levine Cancer InstituteJanssen Biotech IncAmerican Society Of Hematology Annual MeetingDrug AdministrationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonExchange CommissionAmerican Society Of HematologyDivision Of Lymphoma Therapy ResearchCompanies Of JohnsonDepartment Of Hematologic OncologyAnnual MeetingClinical DirectorLymphoma TherapyHematologic OncologyVice PresidentMedical AffairsJanssen BiotechCardiac Failure
Johnson & Johnson : New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia - Vimarsana News

Johnson & Johnson : New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia

Published: December 10, 2022

NEW ORLEANS, December 10, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study , which... | December 10, 2022

Source: marketscreener.com
Related Topics:
United StatesCraig TendlerObinutuzumab ClbCarsten NiemannChristie CorbettNone Of The Janssen Pharmaceutical CompaniesGlobal Medical AffairsSlate DevelopmentJanssen Biotech IncAmerican Society Of Hematology Annual MeetingDrug AdministrationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonExchange CommissionAmerican Society Of HematologyCompanies Of JohnsonInternational WorkshopAmerican Cancer SocietyClinical Associate ProfessorPrincipal InvestigatorHazard RatioVice PresidentJanssen ResearchJanssen Biotech
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio - Vimarsana News

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio

Published: November 3, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today...

Source: prnewswire.com
Related Topics:
United StatesHemophagocytic LymphohistiocytosisObrian KenneyTyrone BrewerPeter LebowitzCaroline PavisJanssen Biotech IncEuropean Hematology AssociationMomenta Pharmaceuticals IncJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of HematologyUniversity Of MunichNone Of The Janssen Pharmaceutical CompaniesOther Administration ReactionsDrug AdministrationEuropean CommissionExchange CommissionCompanies Of JohnsonInternational Myeloma Society Annual MeetingLegend Biotech United States IncAmerican SocietyAnnual MeetingNew Orleans
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease - Vimarsana News

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease

Published: August 25, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved...

Source: prnewswire.com
Related Topics:
Craig TendlerChristie CorbettSusan StewartJanssen ResearchJanssen Biotech IncJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonTranslational SciencesDiagnostics Medical AffairsGlobal Head Of Late DevelopmentNational Comprehensive Cancer NetworkNone Of The Janssen Pharmaceutical CompaniesNational CenterDrug AdministrationExchange CommissionHematology Oncology Janssen Research DevelopmentCompanies Of JohnsonSeattle ChildrenExecutive DirectorConfidence IntervalGlobal HeadSlate DevelopmentMedical AffairsOncology Janssen Research